The limited response of DIPG to widely used therapeutic classes necessitates the development of novel treatments. One such treatment that can be rapidly translated to the clinic is an antibody-drug conjugate (ADC). ADCs are a class of immunoconjugates which chemically link protein-specific antibodies with cytotoxic agents to target antigen-expressing cells with high specificity. ADCs enable specific targeting of the Interleukin-13 cell surface receptor (IL13Rα2) abundantly expressed in DIPG cells but notably absent in surrounding normal brain tissue while avoiding the life-threatening immune inflammatory responses induced by immune-modulating therapies.
Support from The Lyla Nsouli Foundation allows cc-TDI researchers to optimize a pre-clinically validated IL13Rα2-targeting antibody-drug conjugate (ADC) for rapid clinical translation. The Lyla Nsouli Foundation for Children’s Brain Cancer Research (www.lylansoulifoundation.org) was founded in 2012 in honor and memory of Lyla Nsouli who at the age of two was diagnosed with DIPG and given months to live. The Foundation’s main objective is to target DIPG and other underserved brain cancers through research to develop life-saving treatment options.
About cc-TDI: The Children’s Cancer Therapy Development Institute (cc-TDI, www.cc-tdi.org), is a non-profit biotech organization whose mission is to translate scientific discovery into clinical trials by understanding and providing new disease-specific treatment options for children with cancer. cc-TDI’s research team of biologists and biomedical engineers work closely to identify targets on cancer cells and provide evidence-based testing for the selection of new drugs to be used in childhood cancer phase I and phase II clinical trials.
cc-TDI Media Contact: Erika Ellis, Communications Lead ([email protected]). Social media: Facebook and Twitter @cctdilab, Instagram @cctdi, LinkedIn @Children’s Cancer Therapy Development Institute.
Children’s Cancer Therapy Development Institute
Visit us on social media: